Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> PI3K/Akt/mTOR Signaling >> mTOR

mTOR

MTOR (mechanistic target of rapamycin) is a serine/threonine kinase that regulates cellular metabolism, growth ad survival. It mediates the cellular response to stress, growth factor and hormone etc. It is involved in cancer, aging and neurodegenerative diseases etc.

Products for  mTOR

  1. Cat.No. Product Name Information
  2. GC17330 (+)-Usniacin (+)-Usniacin is isolated from isolated from lichens, binds at the ATP-binding pocket of mTOR, and inhibits mTORC1/2 activity. (+)-Usniacin inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer activity. (+)-Usniacin possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium. (+)-Usniacin Chemical Structure
  3. GC63524 (32-Carbonyl)-RMC-5552 (32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC50s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2). (32-Carbonyl)-RMC-5552 Chemical Structure
  4. GC32767 3BDO

    3-Benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3H)-one

     A butyrolactone derivative and autophagy inhibitor 3BDO Chemical Structure
  5. GC73642 ALK-IN-26 ALK-IN-26 is an ALK inhibitor with IC50 value of 7.0 μM for ALK tyrosine kinase. ALK-IN-26 Chemical Structure
  6. GC35395 Arnicolide D

    ARD

     Arnicolide D is a sesquiterpene lactone isolated from Centipeda minima. Arnicolide D modulates the cell cycle, activates the caspase signaling pathway and inhibits the PI3K/AKT/mTOR and STAT3 signaling pathways. Arnicolide D inhibits Nasopharyngeal carcinoma (NPC) cell viability in a concentration- and time-dependent manner. Arnicolide D Chemical Structure
  7. GC74029 ASCT2-IN-1 ASCT2-IN-1 (compound 20k) is an ASCT2 inhibitor with IC50 values of 5.6 μM and 3.5 μM in cells A549 and HEK293, respectively. ASCT2-IN-1 Chemical Structure
  8. GC74030 ASCT2-IN-2 ASCT2-IN-2 (compound 25e) is an ASCT2 inhibitor with IC50 of 5.14 μM. ASCT2-IN-2 Chemical Structure
  9. GC13029 AZD2014

    AZD 2014; AZD-2014

     AZD2014 (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes. AZD2014 Chemical Structure
  10. GC16380 AZD8055

    CCG-168

    AZD8055 is a new ATP-competitive mTOR inhibitor with an IC50 of 0.8 nmol/L and a Ki of 1.3 nmol/L.

     AZD8055 Chemical Structure
  11. GC13271 BEZ235 Tosylate BEZ235 Tosylate Chemical Structure
  12. GC35509 BGT226

    NVP-BGT226

     BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells. BGT226 Chemical Structure
  13. GC30229 Cbz-B3A Cbz-B3A is a potent and selective inhibitor of mTORC1 signaling that appear to bind to ubiquilins 1, 2, and 4, and Cbz-B3A inhibits the phosphorylation of eIF4E-binding protein 1 (4EBP1). Cbz-B3A Chemical Structure
  14. GC16654 CC-115 mTOR/DNA-PK inhibitor CC-115 Chemical Structure
  15. GC34121 CC-115 hydrochloride CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling. CC-115 hydrochloride Chemical Structure
  16. GC13648 CC-223

    CC-223; ATG-008

     CC-223 (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. CC-223 inhibits both mTORC1 and mTORC2. CC-223 Chemical Structure
  17. GC65944 CC214-2 CC214-2 is a potent and dual inhibitor of mTORC1/mTORC2. Mycobacterium tuberculosis modulates mammalian target of rapamycin (mTOR) signaling to impede autophagy. CC214-2 has the potential to shorten the duration of TB. CC214-2 Chemical Structure
  18. GC38419 Cyclovirobuxine D

    CVB-D, NSC 91722

     An alkaloid with diverse biological activities Cyclovirobuxine D Chemical Structure
  19. GC19114 CZ415 CZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07. CZ415 Chemical Structure
  20. GC18583 D-α-Hydroxyglutaric Acid

    D-2-HG, D-2-Hydroxyglutaric Acid

     Over-produced in the human neurometabolic disease D-2-HGA D-α-Hydroxyglutaric Acid Chemical Structure
  21. GC72768 Desmethyl-VS-5584 hydrochloride

    Desmethyl-SB2343 hydrochloride

     Desmethyl-VS-5584 hydrochloride is a dimethyl analog of VS-5584, a potent and selective dual mTOR/PI3K inhibitor, with a pyridine[2,3-d]pyrimidine structure. Desmethyl-VS-5584 hydrochloride Chemical Structure
  22. GC68980 Dihydroevocarpine

    Dihydroevocarpine induces acute myeloid leukemia cell toxicity by inhibiting mTORC1/2 activity.

     Dihydroevocarpine Chemical Structure
  23. GN10583 Dihydromyricetin

    (+)-Dihydromyricetin

     Dihydromyricetin is a natural flavanonol isolated from A. grossedentata and H. dulcis that has antioxidant, antiproliferative, anti-apoptotic, and anti-alcohol intoxication properties. Dihydromyricetin Chemical Structure
  24. GC62495 DS-7423 DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity. DS-7423 Chemical Structure
  25. GC43585 eCF309 eCF309 is an ATP-competitive inhibitor of mTOR (IC50 = 15 nM in vitro and in cells) with >65-fold selectivity over other kinases, including PI3Ks. eCF309 Chemical Structure
  26. GC10196 ETP-46464

    ATM Inhibitor III, ATR Inhibitor III

     ATR inhibitor,potent and selective ETP-46464 Chemical Structure
  27. GC13601 Everolimus (RAD001)

    RAD001

     Everolimus (RAD001) is an orally active derivative of rapamycin that inhibits the Ser/Thr kinase, mTOR (mammalian target of rapamycin). Everolimus (RAD001) Chemical Structure
  28. GC33355 FT-1518 FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity. FT-1518 Chemical Structure
  29. GC10228 GDC-0084 PI3K and mTOR inhibitor, brain-permeable GDC-0084 Chemical Structure
  30. GC12021 GDC-0349 MTOR inhibitor GDC-0349 Chemical Structure
  31. GC11177 GDC-0980 (RG7422)

    Apitolisib, RG7422

     GDC-0980 (RG7422) (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with aKiof 17 nM for mTOR. GDC-0980 (RG7422) Chemical Structure
  32. GC10900 GDC-mTOR inhibitor GDC-mTOR inhibitor Chemical Structure
  33. GC17338 GNE-317 potent, brain-penetrant PI3K inhibitor GNE-317 Chemical Structure
  34. GC10340 GNE-477 dual PI3K/mTOR inhibitor GNE-477 Chemical Structure
  35. GC15423 GNE-493

    Pan-PI3K/mTOR inhibitor

     GNE-493 Chemical Structure
  36. GC11018 GSK1059615 PI3K and mTOR inhibitor,potent and reversible GSK1059615 Chemical Structure
  37. GC15072 GSK2126458

    GSK212; GSK-2126458; GSK 2126458; GSK-212; GSK 212

     GSK2126458 (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. GSK2126458 has anti-cancer activity. GSK2126458 Chemical Structure
  38. GA10282 H-Leu-OH

    Leu, NSC 46709, Pentanoic Acid

     H-Leu-OH Chemical Structure
  39. GC65460 HDACs/mTOR Inhibitor 1 HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies, with IC50s of 0.19 nM, 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1 Chemical Structure
  40. GC38088 Hederacolchiside A1 Hederacolchiside A1 Chemical Structure
  41. GC62572 hSMG-1 inhibitor 11e hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC50 of 900-fold selectivity over mTOR (IC50 of 45 nM), PI3Kα/γ (IC50s of 61 nM and 92 nM) and CDK1/CDK2 (IC50s of 32 μM and 7.1 μM). hSMG-1 inhibitor 11e Chemical Structure
  42. GC61925 hSMG-1 inhibitor 11j hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 μM). hSMG-1 inhibitor 11j can be used for the research of cancer. hSMG-1 inhibitor 11j Chemical Structure
  43. GC72931 HTH-01-091 TFA HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 TFA Chemical Structure
  44. GC73729 IBL-302

    AMU302

     IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 Chemical Structure
  45. GC10969 INK 128(MLN0128)

    INK128; INK-128

     INK 128 (MLN0128) (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase. INK 128(MLN0128) Chemical Structure
  46. GC34909 JR-AB2-011 A selective mTORC2 inhibitor JR-AB2-011 Chemical Structure
  47. GC73992 KTC1101 KTC1101 is an orally active pan-PI3K inhibitor. KTC1101 Chemical Structure
  48. GC14346 KU-0060648 Dual DNA-PK/PI3-K inhibitor, ATP-competitive KU-0060648 Chemical Structure
  49. GC15167 KU-0063794 MTORC1 and mTORC2 inhibitor KU-0063794 Chemical Structure
  50. GC68037 L-Leucine-1-13C,15N L-Leucine-1-13C,15N Chemical Structure
  51. GC68219 L-Leucine-13C L-Leucine-13C Chemical Structure
  52. GC63833 L-Leucine-15N L-Leucine-15N Chemical Structure
  53. GC66357 L-Leucine-d2 L-Leucine-d2 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. L-Leucine-d2 Chemical Structure
  54. GC64188 L-Leucine-d3 L-Leucine-d3 is a deuterated form of L-Leucine that is used for mass spectrometry (MS) quantification of proteins and as a tracer in metabolic studies. L-Leucine-d3 Chemical Structure
  55. GC69370 Leucine-13C6

    Leucine-13C6 is a 13C-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA) that can activate the mTOR signaling pathway.

     Leucine-13C6 Chemical Structure
  56. GC12045 LY 303511 An inhibitor of cell proliferation LY 303511 Chemical Structure
  57. GC14371 LY3023414

    LY3023414

     LY3023414 (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. LY3023414 potently inhibits mTORC1/2 at low nanomolar concentrations. LY3023414 Chemical Structure
  58. GC64402 MHY-1685 MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration. MHY-1685 Chemical Structure
  59. GC13790 MHY1485 MHY1485 is a potent activator of mTOR, which inhibits autophagy and the fusion between autophagosomes and lysosomes. MHY1485 Chemical Structure
  60. GC65143 MKC-1

    Ro-31-7453

     MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family. MKC-1 Chemical Structure
  61. GC60258 MT 63-78 MT 63-78 is a specific and potent direct AMPK activator with an EC50 of 25 μM. MT 63–78 also induces cell mitotic arrest and apoptosis. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects. MT 63-78 Chemical Structure
  62. GC64304 MTI-31

    LXI-15029

     MTI-31 is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 Chemical Structure
  63. GC65115 mTOR inhibitor-1 mTOR inhibitor-1 is a novel mTOR pathway inhibitor which can suppress cells proliferation and inducing autophagy. mTOR inhibitor-1 Chemical Structure
  64. GC62339 mTOR inhibitor-8 mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells. mTOR inhibitor-8 Chemical Structure
  65. GC72950 NEO214 NEO214 is an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram and perillyl alcohol. NEO214 Chemical Structure
  66. GC18089 Nordihydroguaiaretic acid

    NDGA, NSC 4291

     A non-selective LO inhibitor Nordihydroguaiaretic acid Chemical Structure
  67. GC33014 NSC781406 A dual inhibitor of PI3K and mTOR NSC781406 Chemical Structure
  68. GC63121 NV-5138 NV-5138, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2. NV-5138 Chemical Structure
  69. GC63122 NV-5138 hydrochloride NV-5138 hydrochloride, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2. NV-5138 hydrochloride Chemical Structure
  70. GC44475 NVP-BEZ235 (hydrochloride)

    Dactolisib

     NVP-BEZ235 is a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mTOR that is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anticancer agents when used in in vivo combination studies. NVP-BEZ235 (hydrochloride) Chemical Structure
  71. GC16145 NVP-BGT226

    NVP-BGT226 maleate

     BGT226 (NVP-NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells. NVP-BGT226 Chemical Structure
  72. GC14071 OSI-027 MTORC1/ mTORC2 inhibitor OSI-027 Chemical Structure
  73. GC15740 OXA-01 mTORC1 and mTORC2 inhibitor OXA-01 Chemical Structure
  74. GC70464 P-2281 P-2281 is a mTOR inhibitor with anticancer and anti-inflammatory efficacies. P-2281 Chemical Structure
  75. GC12773 Palomid 529

    P529, RES-529, SG 00529

    PI3K/Akt/mTOR inhibitor

     Palomid 529 Chemical Structure
  76. GC16417 PF-04691502 PI3K/mTOR (FRAP) inhibitor PF-04691502 Chemical Structure
  77. GC19283 PF-04979064 PF-04979064 is a potent and selective PI3K/mTOR dual kinase inhibitor with Kis of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively. PF-04979064 Chemical Structure
  78. GC15653 PF-05212384 (PKI-587)

    PK-1587, PKI-587

     PF-05212384 (PKI-587) (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively. PF-05212384 (PKI-587) is equally effective in both complexes of mTOR, mTORC1 and mTORC2. PF-05212384 (PKI-587) Chemical Structure
  79. GC11165 PI-103 Class I PI3K, mTOR and DNA-PK inhibitor PI-103 Chemical Structure
  80. GC16379 PI-103 Hydrochloride

    PI 103 hydrochloride;PI103 hydrochloride

     A potent, cell-permeable PI3K inhibitor PI-103 Hydrochloride Chemical Structure
  81. GC36909 PI3Kα/mTOR-IN-1 PI3Kα/mTOR-IN-1 is a potent PI3Kα/mTOR dual inhibitor, with an IC50 of 7 nM for PI3Kα in a cell assay, and Kis of 10.6 nM and 12.5 nM for mTOR and PI3Kα in a cell free assay , respectively. PI3Kα/mTOR-IN-1 Chemical Structure
  82. GC62140 PKI-179 PKI-179 is a potent and orally active dual PI3K/mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo. PKI-179 Chemical Structure
  83. GC17104 PKI-402

    PI3K inhibitor,selective, reversible and ATP-competitive

     PKI-402 Chemical Structure
  84. GN10709 Polyphyllin A

    (+)-Polyphyllin D

     Polyphyllin A Chemical Structure
  85. GC33115 Pomiferin (NSC 5113) Pomiferin (NSC 5113) (NSC 5113) acts as an potential inhibitor of HDAC, with an IC50 of 1.05 μM, and also potently inhibits mTOR (IC50, 6.2 μM). Pomiferin (NSC 5113) Chemical Structure
  86. GC11003 PP121 Dual inhibitor of tyrosine and phosphoinositide kinases PP121 Chemical Structure
  87. GC15904 PP242

    PP242; PP-242

     PP242 (PP 242) is a selective and ATP-competitive mTOR inhibitor with an IC50 of 8 nM. PP242 inhibits both mTORC1 and mTORC2 with IC50s of 30 nM and 58 nM, respectively. PP242 Chemical Structure
  88. GC33385 PQR-530 A dual inhibitor of PI3Kα and mTOR PQR-530 Chemical Structure
  89. GC19300 PQR309

    PI3K-IN-2

     PQR309 is a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor with IC50s of 33nM, 451nM, 661nM, 708nM and 89nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and mTOR, respectively. PQR309 Chemical Structure
  90. GC32891 PQR620 PQR620 is an orally bioavailable and selective brain penetrant inhibitor of mTORC1/2. PQR620 Chemical Structure
  91. GC18032 QL-IX-55 QL-IX-55 Chemical Structure
  92. GC11607 Rapalink-1 third-generation mTOR inhibitor Rapalink-1 Chemical Structure
  93. GC15031 Rapamycin (Sirolimus)

    AY 22989, NSC 226080, Sirolimus, Wy 090217

     Rapamycin used to be used as an antifungal antibiotic. Rapamycin (Sirolimus) Chemical Structure
  94. GC48027 Rapamycin-d3

    Sirolimus-d3

     An internal standard for the quantification of rapamycin Rapamycin-d3 Chemical Structure
  95. GC39292 Rheb inhibitor NR1 Rheb inhibitor NR1 is a Rheb inhibitor with an IC50 of 2.1??M in the Rheb-IVK assay. Rheb inhibitor NR1 Chemical Structure
  96. GC13071 Ridaforolimus (Deforolimus, MK-8669)

    AP23573, Deforolimus, Ridaforolimus

     Ridaforolimus (Deforolimus, MK-8669) (MK-8669) is a potent and selective mTOR inhibitor; inhibits ribosomal protein S6 phosphorylation with an IC50 of 0.2 nM in HT-1080 cells. Ridaforolimus (Deforolimus, MK-8669) Chemical Structure
  97. GC73678 RMC-4998 RMC-4998 is an orally active inhibitor targeting the active or GTP-bound state of the KRASG12C mutant. RMC-4998 Chemical Structure
  98. GC62649 RMC-5552 RMC-5552 is a potent and selective inhibitor of mTORC1. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC50s of 0.14 nM and 0.48 nM, respectively. RMC-5552 has anti-cancer activity. RMC-5552 Chemical Structure
  99. GC63894 RMC-6272

    RM-006

     RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors. RMC-6272 Chemical Structure
  100. GC38609 Rotundic acid Rotundic acid, a triterpenoid obtained from I. Rotundic acid Chemical Structure
  101. GC64278 RP-3500

    RP-3500; ATR inhibitor 4

     RP-3500 (ATR inhibitor 4) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. RP-3500 shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. RP-3500 has potent antitumor activity. RP-3500 Chemical Structure

Items 1 to 100 of 115 total

per page
  1. 1
  2. 2

Set Descending Direction